Systemic corticosteroids have been widely used as co-adjuvant therapy in patients ARF/ARDS due to influenza pneumonia to modulate lung inflammation, despite controversy on clinical outcomes. Our findings provide solid evidence to support the association of corticosteroids administration with increased ICU mortality in critically ill patients with influenza pneumonia.